PO.TB03.02 · 肿瘤生物学
Keratin 17与胰腺导管腺癌中的上皮-间质转化相关
Keratin 17 correlates with epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:胰腺导管腺癌(PDAC)占所有胰腺恶性肿瘤的90%以上,5年生存率为13%。约80%的患者在晚期确诊,伴有以广泛侵袭为特征的转移性疾病。导致这种转移扩散的关键生物学通路之一是上皮-间质转化(EMT)——一个高度可塑的过程,使癌细胞通过从上皮表型转换为间质表型而获得侵袭特性。Keratin 17(K17)是与不良预后相关的基底样PDAC特征的组成部分,已被证明可促进胰腺癌转移并在膀胱癌、食管癌和肺癌中诱导EMT。在本研究中,我们检验了K17与PDAC中EMT相关的假设,从而促成该疾病的不良预后。
方法:我们对公开可用的数据集(包含42例未经治疗的PDAC)进行了整合性单细胞转录组学分析(scRNA-seq),以鉴定与K17表达相关的癌症相关通路。使用MSigDB的Hallmark基因集和基因本体论(GO)术语,在RStudio中进行差异基因表达和通路富集分析。为验证scRNA-seq结果,我们使用MACSima平台在FFPE组织微阵列上进行了循环多重免疫荧光成像,并在人PDAC样本的全切片FFPE切片上进行了免疫组织化学(IHC)。开展这些分析以评估K17的空间分布及其与通过scRNA-seq鉴定的顶级EMT相关标志物表达的相关性。
结果:scRNA-seq分析显示K17阳性PDAC细胞表现出EMT通路的转录富集,其中ANXA1、S100A4、GPC1、LAMC2、WWTR1和LAMA3被鉴定为顶级相关标志物。多重免疫荧光图像分析证实K17阳性肿瘤区域表现出上皮分化降低,表现为GATA-6和E-cadherin评分低。在scRNA-seq鉴定的标志物中,LAMC2(一种确立的EMT生物标志物)与K17显示出最显著的正相关,并通过IHC得到证实。
结论:K17标记了一个转录上不同且高度侵袭性的PDAC亚群,其特征是强劲的EMT激活。LAMC2成为在转录组和蛋白水平上与K17最密切相关的EMT标志物,提示K17-LAMC2轴可能是PDAC中EMT的主要驱动因素。
查看英文原文 English abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignancies and has a 5-year survival rate of 13%. Approximately, 80% of the patients are diagnosed at later stages with metastatic disease characterized by widespread invasion. One of the key biological pathways that lead to this metastatic spread is Epithelial to Mesenchymal Transition (EMT) - a highly plastic process that allows cancer cells to gain invasive properties by switching from an epithelial to a mesenchymal phenotype. Keratin 17 (K17), a component of the basal-like PDAC signature associated with poor prognosis, has been shown to promote pancreatic cancer metastases and induce EMT in bladder, esophageal, and lung cancers. In this study, we test the hypothesis that K17 is associated with EMT in PDAC, contributing to the poor prognosis of the disease.
Methods: We performed integrative single-cell transcriptomic analyses (scRNA-seq) of publicly available datasets comprising of 42 treatment-naïve PDACs to identify cancer-related pathways associated with K17 expression. Differential gene expression and pathway enrichment analyses were conducted in RStudio using the Hallmark gene sets from MSigDB and Gene Ontology (GO) terms. To validate the scRNA-seq results, we performed cyclic multiplex immunofluorescence imaging using the MACSima platform on FFPE tissue microarrays, along with immunohistochemistry (IHC) on whole-slide FFPE sections of human PDAC samples. These analyses were conducted to assess the spatial distribution of K17 and its correlation with the expression of top EMT-associated markers identified through scRNA-seq.
Results: scRNA-seq analysis revealed that K17-positive PDAC cells exhibited transcriptional enrichment of the EMT pathway, with ANXA1, S100A4, GPC1, LAMC2, WWTR1, and LAMA3 identified as top associated markers. Multiplex immunofluorescence image analysis confirmed that K17-positive tumor regions displayed reduced epithelial differentiation as indicated by low GATA-6 and E-cadherin score. Among the markers identified by scRNA-seq, LAMC2, an established biomarker of EMT, demonstrated the most significant positive correlation with K17 and was confirmed using IHC.
Conclusions: K17 marks a transcriptionally distinct and highly invasive PDAC subpopulation characterized by robust EMT activation. LAMC2 emerges as the EMT marker most closely associated with K17 at both transcriptomic and protein levels, suggesting a K17-LAMC2 axis that maybe a major driver of EMT in PDAC.
利益披露 Disclosure
S. Sarkar, None..
L. Delgado Coka, None..
R. S. Powers, None..
N. Marchenko, None..
K. Shroyer, None.